<DOC>
	<DOCNO>NCT02446496</DOCNO>
	<brief_summary>This open-label , randomize , single dose , two-sequence two-period crossover study , separate 7 day washout interval first Study Drug Administration . This study conduct determine bioequivalence cefadroxil DURICEF™ film coat tablet manufacture Smithkline Beecham Egypt , LLC affiliate co. GalaxoSmithKline ( GSK ) cefadroxil BIODROXIL™ film coat tablet manufacture Kahira Pharm &amp; amp ; Chem .Ind . Co . Novartis Pharma ( NP ) single oral dose administration healthy adult subject fasting condition . In Period 1 , subject randomize receive cefadroxil tablet manufacture either GSK NP . Following washout least 7 day , subject cross Period 2 receive cefadroxil tablet receive Period 1 . DURICEF trademark GSK group company . BIODROXIL trademark Sandoz .</brief_summary>
	<brief_title>A Bioequivalence Study Cefadroxil Film Coated Tablets After A Single Oral Dose Administration Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Cefadroxil</mesh_term>
	<criteria>Healthy male female , age 18 55 year , inclusive . Body weight within 15 percent normal range accord accept normal value body mass index ( BMI ) . Medical demographic without evidence clinically significant deviation normal medical condition . Results clinical laboratory test within normal range deviation consider clinically significant principal investigator . Subject allergy drug investigation . Subjects know allergy product test . Subjects whose value BMI outside accept normal range . Female subject pregnant , nurse take birth control pill . Medical demographic evidence clinically significant deviation normal medical condition . Results laboratory test clinically significant . Acute infection within one week precede first study drug administration . History drug alcohol abuse . Subject agree take prescription nonprescription drug within two week first study drug administration end study . Subject special diet ( example subject vegetarian ) . Subject agree consume beverage foods contain methylxanthenes e.g . caffeine ( coffee , tea , cola , chocolate etc . ) 48 hour prior study administration either study period donate last sample respective period . Subject agree consume beverage foods contain grapefruit 7 day prior first study drug administration end study . Subject history severe disease direct impact study . Participation bioequivalence study clinical study within last 6 week first study drug administration . Subject intend hospitalize within 6 week first study drug administration . Subjects , completion study , would donate 500 milliliter ( mL ) blood 7 day , 750 mL blood 30 day , 1000 mL 90 day , 1250 mL 120 day , 1500 mL 180 day , 2000 mL 270 day , 2500 mL blood 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>film coat tablet</keyword>
	<keyword>cefadroxil</keyword>
</DOC>